Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outset Medical (OM) Operating Leases (2020 - 2025)

Outset Medical (OM) has disclosed Operating Leases for 6 consecutive years, with $5.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases rose 86.66% to $5.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.0 million, a 86.66% increase, with the full-year FY2025 number at $5.0 million, up 86.66% from a year prior.
  • Operating Leases was $5.0 million for Q4 2025 at Outset Medical, up from $1.2 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $7.8 million in Q1 2021 to a low of $1.2 million in Q3 2025.
  • A 5-year average of $4.9 million and a median of $5.1 million in 2023 define the central range for Operating Leases.
  • Biggest YoY gain for Operating Leases was 86.66% in 2025; the steepest drop was 60.6% in 2025.
  • Outset Medical's Operating Leases stood at $6.9 million in 2021, then decreased by 19.11% to $5.6 million in 2022, then dropped by 19.62% to $4.5 million in 2023, then crashed by 40.12% to $2.7 million in 2024, then surged by 86.66% to $5.0 million in 2025.
  • Per Business Quant, the three most recent readings for OM's Operating Leases are $5.0 million (Q4 2025), $1.2 million (Q3 2025), and $1.7 million (Q2 2025).